EGFR and meningioma: Although the precise mechanism by which EGFR inhibitors exert their anti-cancer effect remains unknown, compelling evidence exists to further explore whether inhibitors of EGFR will be of clinical benefit to patients with benign/low-grade or recurrent meningioma, which represent the vast majority of patients.